Merit Medical Systems

Valuation Analysis

About the Company

Merit Medical Systems en bref

Merit Medical Systems (MMSI) is currently trading at 58,60 € with a market capitalization of 3,5 Md €. The trailing P/E ratio stands at 28.97x, with a forward P/E of 15.28x. The 52-week range spans from 52,08 € to 84,33 €; the current price is 30.5% below the yearly high. Year-over-year revenue growth stands at +7.5%. The net profit margin stands at 9.03%.

💰 Dividende

Merit Medical Systems currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

11 analystes évaluent Merit Medical Systems (MMSI) au consensus : Acheter. L'objectif de cours moyen est de 78,07 €, soit un potentiel de +33.21% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 64,51 € à 95,89 €.

Merit Medical Systems : la thèse d'investissement en détail

Merit Medical Systems (MMSI) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 38.8% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Wall Street consensus sits at Buy with an average price target implying roughly 33.21% upside from current levels — analyst sentiment is firmly constructive.

Valorisation en contexte

The PEG ratio at 1.43 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The forward P/E of 15.28x is meaningfully below the trailing 28.97x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 33.21% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (6.68%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Merit Medical Systems?

Compare top-rated brokers — low fees, trusted providers, fully regulated.